Next Article in Journal
Vitamin E Content and Composition in Tomato Fruits: Beneficial Roles and Bio-Fortification
Next Article in Special Issue
Redox-Responsive Porphyrin-Based Polysilsesquioxane Nanoparticles for Photodynamic Therapy of Cancer Cells
Previous Article in Journal
Hydrolysis of Oligosaccharides by a Thermostable α-Galactosidase from Termitomyces eurrhizus
Previous Article in Special Issue
The in Vitro Antimicrobial Efficacy of PDT against Periodontopathogenic Bacteria
 
 
Article

Intravenous Single-Dose Toxicity of Redaporfin-Based Photodynamic Therapy in Rodents

1
Luzitin SA, S. Martinho do Bispo, Coimbra 3045-016, Portugal
2
Bluepharma—Indústria Farmacêutica SA, S. Martinho do Bispo, Coimbra 3045-016, Portugal
3
Faculty of Chemistry, Jagiellonian University, Krakow 30-060, Poland
4
Chemistry Department, University of Coimbra, Coimbra 3004-535, Portugal
*
Author to whom correspondence should be addressed.
Academic Editors: Michael R. Hamblin and Ying-ying Huang
Int. J. Mol. Sci. 2015, 16(12), 29236-29249; https://doi.org/10.3390/ijms161226162
Received: 16 November 2015 / Revised: 30 November 2015 / Accepted: 2 December 2015 / Published: 8 December 2015
(This article belongs to the Special Issue Advances in Photodynamic Therapy)
We assessed the tolerability and safety in rodents of a single intravenous (i.v.) dose of redaporfin, a novel photosensitizer for Photodynamic Therapy (PDT) of cancer. Two approaches were used to evaluate acute toxicity: (i) a dose escalation study in BALB/c mice to evaluate the maximum tolerated dose of redaporfin; and (ii) a safety toxicology study in Wistar rats, of a single dose of redaporfin, with or without illumination, to evaluate possible signs of systemic toxicity. Redaporfin formulation was well tolerated by mice, with no signs of adverse reactions up to 75 mg/kg. In rats, there were no relevant changes, except for a significant, but transient, increase in the blood serum markers for hepatic function and muscle integrity, and also on neutrophil counts, observed after the application of light. The overall results showed that redaporfin-PDT is very well tolerated. No abnormalities were observed, including reactions at the injection site or skin phototoxicity, although the animals were maintained in normal indoor lighting. Redaporfin also showed a high efficacy in the treatment of male BALB/c mice with subcutaneously implanted colon (CT26) tumours. Vascular-PDT with 1.5 mg/kg redaporfin and a light dose of 74 J/cm2 led to the complete tumour regression in 83% of the mice. View Full-Text
Keywords: photodynamic therapy; cancer treatment; bacteriochlorin; redaporfin; intravenous formulation; single-dose toxicity; rodents photodynamic therapy; cancer treatment; bacteriochlorin; redaporfin; intravenous formulation; single-dose toxicity; rodents
Show Figures

Graphical abstract

MDPI and ACS Style

Rocha, L.B.; Schaberle, F.; Dąbrowski, J.M.; Simões, S.; Arnaut, L.G. Intravenous Single-Dose Toxicity of Redaporfin-Based Photodynamic Therapy in Rodents. Int. J. Mol. Sci. 2015, 16, 29236-29249. https://doi.org/10.3390/ijms161226162

AMA Style

Rocha LB, Schaberle F, Dąbrowski JM, Simões S, Arnaut LG. Intravenous Single-Dose Toxicity of Redaporfin-Based Photodynamic Therapy in Rodents. International Journal of Molecular Sciences. 2015; 16(12):29236-29249. https://doi.org/10.3390/ijms161226162

Chicago/Turabian Style

Rocha, Luis B., Fábio Schaberle, Janusz M. Dąbrowski, Sérgio Simões, and Luis G. Arnaut. 2015. "Intravenous Single-Dose Toxicity of Redaporfin-Based Photodynamic Therapy in Rodents" International Journal of Molecular Sciences 16, no. 12: 29236-29249. https://doi.org/10.3390/ijms161226162

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop